RxDoctor Payments Data

William Boulware, MD

Internal Medicine · Liberty, MONPI 1023190493

Payments from drug & device makers

$6,541in general payments, 2019–2025

Across 431 payments — averaging $15.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$919
  • Novo Nordisk$472
  • Pfizer$463
  • Lilly USA, LLC$459
  • Amgen$407
  • Sunovion Pharmaceuticals Inc.$257
  • plus $4K from 50 others

What the payments were for

  • Food & beverage$6,541100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)67$919
Novo Nordisk28$472
Pfizer36$463
Lilly USA, LLC25$459
Amgen26$407
Sunovion Pharmaceuticals Inc.21$257
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC14$211
Otsuka America Pharmaceutical, Inc.9$210
Astellas Pharma US Inc12$208
Merck14$203
AstraZeneca10$178
Johnson & Johnson(2 entities)11$169
Abbott9$166
Boehringer Ingelheim10$130
Kowa Pharmaceuticals America, Inc.26$128
Sumitomo Pharma America, Inc.7$124
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)6$117
Amarin Pharma, Inc.6$117
E.r. Squibb & Sons, L.L.C.7$100
GSK7$97
Mylan Specialty L.p.7$89
Jazz Pharmaceuticals Inc.5$89
Phathom Pharmaceuticals, Inc.5$87
Takeda Pharmaceuticals U.S.A., Inc.5$86
Novartis4$75
Biohaven Pharmaceuticals, Inc.3$69
Axsome Therapeutics, Inc.4$68
Tolmar, Inc.4$66
Viatris Specialty LLC3$57
Vanda Pharmaceuticals Inc.2$55
Collegium Pharmaceutical, Inc.3$55
Melinta Therapeutics, LLC4$49
Corcept Therapeutics2$46
Lundbeck LLC2$42
Daiichi Sankyo Inc.2$42
Biohaven Pharmaceutical Holding Company Ltd.2$35
Sun Pharmaceutical Industries Inc.2$33
Esperion Therapeutics, Inc.2$32
Antares Pharma, Inc.2$31
Inspire Medical Systems, Inc.1$29
Fidia Pharma USA Inc.1$25
Fresenius Kabi USA, LLC1$21
Ardelyx, Inc.1$21
Eisai Inc.1$20
Tonix Medicines, Inc.1$20
Insulet Corporation1$18
Verona Pharma, Inc.1$17
Paratek Pharmaceuticals, Inc.1$17
Biogen1$16
Regeneron Healthcare Solutions, Inc.1$16
Xeris Pharmaceuticals, Inc.1$15
Sanofi-aventis U.S. LLC1$14
Medtronic1$13
Idorsia Pharmaceuticals US Inc1$13
Scilex Pharmaceuticals Inc.1$12
Teva Pharmaceuticals USA, Inc.1$12

How this compares

$6,541 in reported general payments places this provider in the 90th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$190,429
Medicare patients
261
Services billed
4,730

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban236$194,175
OzempicSemaglutide116$124,473
JardianceEmpagliflozin89$76,691
MounjaroTirzepatide69$76,002
EntrestoSacubitril/Valsartan66$71,341
LinzessLinaclotide37$31,493
Repatha SureclickEvolocumab32$23,401
ProliaDenosumab13$22,721
MyrbetriqMirabegron47$22,501
XareltoRivaroxaban37$21,886
TrulicityDulaglutide17$20,941
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$19,744
TradjentaLinagliptin27$15,852
Aimovig AutoinjectorErenumab-Aooe13$15,409
JanuviaSitagliptin Phosphate22$15,278

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$463$197,828248 claims
Novo NordiskOzempic$472$124,473116 claims
Boehringer IngelheimJardiance, Tradjenta, Glyxambi$130$103,791132 claims
Lilly USA, LLCMounjaro, Trulicity$459$96,94386 claims
NovartisEntresto$75$71,34166 claims
AbbVieLinzess$919$31,49337 claims
AmgenProlia$407$22,72113 claims
Astellas Pharma US IncMyrbetriq$208$22,50147 claims
Johnson & JohnsonXarelto$169$21,88637 claims
GSKTrelegy Ellipta$97$19,74429 claims
MerckJanuvia$203$15,27822 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$12$5,46615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Liberty

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →